Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds
Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any point in a treatment regimen, according to a real-life study in the U.S. The study, “A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer,” was published in the journal Advances in Therapy. “Men with mCRPC who received [Provenge] had a significant improvement in median overall survival and reduction in the risk of death at three years, regardless of line of use,” Rana R. McKay, MD, the study’s lead author, said in a press release. McKay is a medical oncologist and assistant professor of medicine at Moores Cancer CenterUniversity of California San Diego.
Subscribe or to access all post and page content.